Karel Kostev to Diabetes Mellitus, Type 2
This is a "connection" page, showing publications Karel Kostev has written about Diabetes Mellitus, Type 2.
Connection Strength
2.633
-
Change in glucose-lowering medication regimens in individuals with type 2 diabetes mellitus during the COVID-19 pandemic in Germany. Diabetes Obes Metab. 2021 04; 23(4):910-915.
Score: 0.196
-
Differences in baseline characteristics between type 2 diabetes mellitus patients treated with dipeptidyl peptidase-4 inhibitors in randomized controlled trials and those receiving the same treatment in real-world settings?. Int J Clin Pharmacol Ther. 2018 Sep; 56(9):411-416.
Score: 0.167
-
Association of characteristics of people with type 2 diabetes mellitus with discordant values of fasting glucose and HbA1c. J Diabetes. 2018 Dec; 10(12):934-941.
Score: 0.166
-
Increased depression symptom score in newly diagnosed type 2 diabetes patients. Psychiatry Res. 2018 03; 261:259-263.
Score: 0.159
-
Changes in patient characteristics, glucose lowering treatment, glycemic control and complications in type 2 diabetes in general practices (Disease Analyzer, Germany: 2008-2016). Postgrad Med. 2018 Mar; 130(2):244-250.
Score: 0.159
-
Association Between the Use of Antihyperglycemic Drugs and Dementia Risk: A Case-Control Study. J Alzheimers Dis. 2018; 66(2):725-732.
Score: 0.159
-
Association between depression and persistence with oral antihyperglycemic drugs in type 2 diabetes mellitus patients in Germany. Psychiatry Res. 2018 03; 261:90-93.
Score: 0.159
-
Low annual frequency of HbA1c testing in people with Type 2 diabetes in primary care practices in Germany. Diabet Med. 2018 02; 35(2):249-254.
Score: 0.159
-
Persistence With Oral Antihyperglycemic Drugs in Type 2 Diabetes Mellitus Patients With Dementia in Germany. J Diabetes Sci Technol. 2018 01; 12(1):140-144.
Score: 0.154
-
Prescription Patterns and Disease Control in Type 2 Diabetes Mellitus Patients in Nursing Home and Home Care Settings: A Retrospective Analysis in Germany. J Diabetes Sci Technol. 2018 01; 12(1):136-139.
Score: 0.153
-
Seasonality of Insulin Use in German Outpatients With Diabetes: A Retrospective Analysis. J Diabetes Sci Technol. 2017 09; 11(5):996-1000.
Score: 0.152
-
Risk of Nonfatal Stroke in Type 2 Diabetes Mellitus Patients: A Retrospective Comparison Between Disease Management Programs and Standard Care. J Diabetes Sci Technol. 2017 07; 11(4):808-813.
Score: 0.150
-
Association of dipeptidyl peptidase 4 inhibitors with risk of metastases in patients with type 2 diabetes and breast, prostate or digestive system cancer. J Diabetes Complications. 2017 Apr; 31(4):687-692.
Score: 0.149
-
Changes in Glycemic Control and Body Weight After Initiation of Dapagliflozin or Basal Insulin Supported Oral Therapy in Type 2 Diabetes: A Primary Care Database Study. J Diabetes Sci Technol. 2017 05; 11(3):590-596.
Score: 0.149
-
Risk of hypoglycaemia in type 2 diabetes patients under different insulin regimens: a primary care database analysis. Ger Med Sci. 2015; 13:Doc01.
Score: 0.130
-
Duration of first prescribed long acting insulin therapy in type 2 diabetes. Diabetes Res Clin Pract. 2012 Jul; 97(1):e3.
Score: 0.106
-
Effects of the COVID-19 lockdown on primary health care for persons with type 2 diabetes - Results from the German Disease Analyzer database. Diabetes Res Clin Pract. 2021 Sep; 179:109002.
Score: 0.051
-
[Effect of the Disease Management Program on HbA1c Value in Type 2 Diabetes Mellitus Patients: A Retrospective Comparison between Disease Management Programs and Standard Care]. Dtsch Med Wochenschr. 2017 Oct; 142(21):e148-e155.
Score: 0.039
-
Fracture risk reduction with use of dipeptidyl peptidase-4 inhibitors: response to Driessen et al. Osteoporos Int. 2017 08; 28(8):2431.
Score: 0.039
-
Use of dipeptidyl peptidase-4 inhibitors and risk of bone fracture in patients with type 2 diabetes in Germany-A retrospective analysis of real-world data. Osteoporos Int. 2017 08; 28(8):2421-2428.
Score: 0.038